Prohibits any health insurer, pharmacy benefit manager, manufacturer or other third-party payor from discriminating against any 340B entity participating in a drug discount program.
S0114 creates the “Defending Affordable Prescription Drug Costs Act” and adds a new chapter to Rhode Island law governing how 340B covered entities and their contract pharmacies are treated by health insurers, pharmacy benefit managers, pharmaceutical manufacturers, and other third-party payors. The bill bars those entities from discriminating against 340B participants in reimbursement, network participation, audits, claims documentation requirements, contract terms, or patient access to prescription drugs. It also prohibits manufacturers and their affiliates from interfering with a 340B entity’s ability to acquire or receive 340B drugs through a contract pharmacy, unless federal law or HHS rules prohibit the arrangement.
The bill also imposes new reporting obligations on 340B covered entities. Each year, participating entities must submit detailed information to the governor, legislative leaders, and the auditor general about acquisition costs, payments received and made, vendors and contract pharmacies used, claim counts, program savings, audits, and compliance oversight. The auditor general is given authority to investigate complaints, enforce compliance, and adopt rules, and violations are tied to Rhode Island’s deceptive trade practices and unfair sales practices laws, creating potential penalties under those statutes. The act takes effect October 1, 2025.
Its practical impact is to strengthen legal protections for hospitals, clinics, and other providers participating in the federal 340B drug discount program, while limiting the ability of insurers, PBMs, and manufacturers to impose special restrictions on those entities. It also increases transparency and state oversight by requiring public reporting of 340B program finances and operations. The bill expressly excludes Medicaid reimbursement arrangements and includes a federal preemption clause to avoid conflict with federal law.
The overall sentiment reflected in the voting history appears strongly favorable, with multiple unanimous or near-unanimous passage votes and only a small number of dissenting votes on one concurrence vote. That pattern suggests broad legislative support for protecting 340B entities and preserving access to discounted prescription drugs. No committee transcript was provided, so there is no recorded floor or committee debate to indicate broader public testimony or detailed concerns.
The main point of contention likely centers on the bill’s impact on insurers, PBMs, and pharmaceutical manufacturers, who may view the restrictions as limiting their contracting, audit, network, and pricing practices. Another possible area of concern is the extensive reporting requirement for 340B entities, which could be seen as burdensome even as it is intended to increase accountability. The bill attempts to address legal concerns by preserving preferred networks, excluding Medicaid, and stating that it should not conflict with federal law.
The bill adds a new chapter to Title 5 of the Rhode Island General Laws and makes discriminatory treatment of 340B covered entities and contract pharmacies unlawful. It also links violations to the state’s deceptive trade practices and unfair sales practices laws, giving the attorney general/auditor general enforcement-related tools and potential penalties. The act does not alter Medicaid reimbursement rules and is written to operate consistently with federal 340B law and other applicable federal requirements.
The voting record shows broad support for the measure, including several unanimous passage votes and only limited opposition on one concurrence vote. That suggests the bill was generally viewed as a consumer- and provider-protection measure aimed at preserving access to discounted prescription drugs. Because no committee transcripts were provided, there is no detailed record of debate, but the final votes indicate a favorable overall sentiment.
The likely controversy is between 340B hospitals, clinics, and contract pharmacies on one side and health insurers, PBMs, manufacturers, and other payors on the other. Opponents may object to limits on reimbursement differentials, network exclusions, audit demands, and contract restrictions, while supporters would argue those practices undermine the federal 340B program. The bill’s new reporting requirements may also draw concern from covered entities because they require detailed annual disclosures about finances, vendors, claims, and compliance activities.